Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -1.67%53 Net Current Asset Value is ₹70.96 as of Mar. 2026, which is 100% below its 10-year median of 27.54. GuruFocus rates NSE:REMUS with a GF Score™ of 53/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 75 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 85.33% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Remus Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was ₹70.96.
The historical rank and industry rank for Remus Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
NSE:REMUS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.85 Med: 27.54 Max: 29.58
Current: 10.12
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Remus Pharmaceuticals was 29.58. The lowest was 8.85. And the median was 27.54.
NSE:REMUS's Price-to-Net-Current-Asset-Value is ranked worse than 85.33% of 75
companies
in the Medical Distribution industry
Industry Median: 3.29
vs NSE:REMUS: 10.12
Remus Pharmaceuticals (NSE:REMUS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Remus Pharmaceuticals Net Current Asset Value Related Terms
Remus Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals Net Current Asset Value Chart
NSE:REMUS vs MCK, CAH, COR: Net Current Asset Value Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹70.96 mean?
Remus Pharmaceuticals (NSE:REMUS) has a Net Current Asset Value of ₹70.96 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Remus Pharmaceuticals and its competitors. This is 158% above median its historical median of 27.54. Over the past decade, Remus Pharmaceuticals' Net Current Asset Value has ranged from 8.85 to 29.58. According to the industry distribution chart, Remus Pharmaceuticals ranks #64 out of 75 companies in the Medical Distribution industry, placing it in the top 85.3%.
Is Remus Pharmaceuticals' Net Current Asset Value too high?
Remus Pharmaceuticals' current Net Current Asset Value of ₹70.96 is 158% above median its 10-year median of 27.54. Over the past 10 years, this metric has ranged from a low of 8.85 to a high of 29.58. Based on the distribution chart, Remus Pharmaceuticals ranks #64 out of 75 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Net Current Asset Value compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #64 out of 75 companies for Net Current Asset Value. This places Remus Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 3.29. Historically, Remus Pharmaceuticals' own Net Current Asset Value has ranged from 8.85 to 29.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.29, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Net Current Asset Value is ₹70.96, which is 158% above median its own 10-year median of 27.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹717.90 — trading 65.3% below its estimated fair value. The current Net Current Asset Value is ₹70.96, which is 158% above median its 10-year median of 27.54. Remus Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Net Current Asset Value is ₹70.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹717.90 is trading 65.3% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Net Current Asset Value: ₹70.96 (158% above median its 10-year median of 27.54)
GF Value™: ₹2,071.36 vs. price of ₹717.90 (65.3% below fair value)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
53GF Score
Get the complete analysis for NSE:REMUS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
